Regenxbio (RGNX) EBIAT (2016 - 2025)
Historic EBIAT for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$61.9 million.
- Regenxbio's EBIAT fell 393.31% to -$61.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$177.9 million, marking a year-over-year increase of 2549.78%. This contributed to the annual value of -$227.1 million for FY2024, which is 1381.13% up from last year.
- Per Regenxbio's latest filing, its EBIAT stood at -$61.9 million for Q3 2025, which was down 393.31% from -$70.9 million recorded in Q2 2025.
- Regenxbio's 5-year EBIAT high stood at $294.0 million for Q4 2021, and its period low was -$76.7 million during Q1 2022.
- In the last 5 years, Regenxbio's EBIAT had a median value of -$61.9 million in 2023 and averaged -$40.5 million.
- Examining YoY changes over the last 5 years, Regenxbio's EBIAT showed a top increase of 73584.91% in 2021 and a maximum decrease of 76437.27% in 2021.
- Quarter analysis of 5 years shows Regenxbio's EBIAT stood at $294.0 million in 2021, then plummeted by 120.38% to -$59.9 million in 2022, then dropped by 4.93% to -$62.9 million in 2023, then increased by 18.61% to -$51.2 million in 2024, then decreased by 21.01% to -$61.9 million in 2025.
- Its EBIAT was -$61.9 million in Q3 2025, compared to -$70.9 million in Q2 2025 and $6.1 million in Q1 2025.